168608-39-7

Usage

Uses

Used in Organic Synthesis:
(3S,4S,5R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)tetrahydrofuran-2,3,4-triol is used as a building block for the synthesis of various complex organic molecules. Its unique structure and functional groups allow it to participate in a wide range of chemical reactions, making it a valuable precursor for the creation of more intricate molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (3S,4S,5R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)tetrahydrofuran-2,3,4-triol is used as a key intermediate in the development of new drugs. Its specific stereochemistry and functional groups can be exploited to design and synthesize novel bioactive compounds with potential therapeutic applications.
Used in Material Science:
(3S,4S,5R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)tetrahydrofuran-2,3,4-triol can also be utilized in material science for the development of new materials with specific properties. Its structural features and reactivity make it a promising candidate for the synthesis of advanced materials with applications in various fields, such as electronics, coatings, and adhesives.
Used in Chemical Research:
As a complex organic compound with unique structural features, (3S,4S,5R)-5-(((tert-butyldiphenylsilyl)oxy)methyl)tetrahydrofuran-2,3,4-triol is used in chemical research to study various aspects of organic chemistry, including reaction mechanisms, stereochemistry, and the development of new synthetic methods. Its versatile reactivity and structural characteristics make it an interesting subject for scientific investigation.

Upstream product

• 532-20-7 D-arabinofuranose 
• 33729-92-9 tert-butyldiphenylsilane 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 28697-53-2 D-arabinopyranose 
• 10323-20-3 D-Arabinose 

Downstream Products

• 114738-04-4 (3aS,5R,6R,6aS)-5-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-6-ol 
• 845868-93-1 1,2,3-tri-O-acetyl-5-O-t-butyldiphenylsilyl-D-arabinofuranose 
• 1220093-28-6 3-deoxy-1,2-O-isopropylidene-β-D-threo-pentofuranose 5-diphenylphosphate 
• 1220093-26-4 5-O-t-butyldiphenylsilyl-3-O-(imidazolylthiocarbonyl)-1,2-O-isopropylidene-β-D-threo-pentofuranose 
• 168969-77-5 [(3aS,5S,6aS)-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-5-yl]methoxy-tert-butyl-diphenyl-silane 
• 1294500-47-2 methyl 2,4-anhydro-5-azido-5-deoxy-3-O-benzyl-D-ribonate 
• 1294500-45-0 5-azido-3-O-benzyl-1,2-O-isopropylidene-β-D-arabinofuranose 
• 1294500-46-1 5-azido-3-O-benzyl-5-deoxy-D-arabinono-1,4-lactone 
• 40429-53-6 5-O-p-toluenesulfonyl-3-O-benzyl-1,2-O-isopropylidene-β-D-arabinofuranose 
• 19139-80-1 ((3aS,5R,6R,6aS)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methanol 
• 168103-00-2 (((3aS,5R,6R,6aS)-6-(benzyloxy)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methoxy)(tert-butyl)diphenylsilane 
• 161469-43-8 (S)-3-((tert-butyldiphenylsilyl)oxy)propane-1,2-diol 
• 172751-32-5 5-O-(tert-butyldiphenylsilyl)-1,2-O-isopropylidene-β-D-threo-pentofuranose-3-ulose 
• 133048-89-2 5-O-tert-butyldiphenylsilyl-1,2-O-isopropylidene-β-D-lyxofuranose 

Relevant academic research and scientific papers

Elongation of the side chain by linear alkyl groups increases the potency of salacinol, a potent α-glucosidase inhibitor from the Ayurvedic traditional medicine “Salacia,” against human intestinal maltase

Four chain-extended analogs (12a–12d) and two related de-O-sulfonated analogs (13a and 13c) by introducing alkyl groups (a: R = C3H7, b R = C6H13, c: R = C8H17, d: R = C10H2

The Miharamycins and Amipurimycin: their Structural Revision and the Total Synthesis of the Latter

The structural puzzle of amipurimycin, a peptidyl nucleoside antibiotic, is solved by total synthesis and X-ray diffraction analysis, with the originally proposed configurations at C3′ and C8′ inverted and those at C6′, C2′′, and C3′′ corrected. A similar structural revision of the relevant miharamycins is proposed via chemical transformations and then validated by X-ray diffraction analysis. The miharamycins bear an unusual trans-fused dioxabicyclo[4.3.0]nonane sugar scaffold, which was previously assigned as being in the cis configuration.

CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS

The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

Structure-activity relationship studies on acremomannolipin A, the potent calcium signal modulator with a novel glycolipid structure 3: Role of the length of alditol side chain

Abstract Five homologs of a novel glycolipid acremomannolipin A (1a), the potential Ca2+ signal modulator isolated from Acremonium strictum, bearing alditols of different length (1g-1k) were synthesized by a stereoselective β-mannosylation of a

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF

Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.

Synthesis and biological evaluation of arabinose 5-phosphate mimics modified at position five

A set of new metabolically stable arabinose 5-phosphate analogues possessing phosphate mimetic groups at position 5 was synthesised. Their ability to interact with arabinose 5-phosphate isomerase from Pseudomonas aeruginosa was evaluated by STD-NMR studie

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to halogenated nucleosides optionally conjugated to a phosphorus oxide or pharmaceutically acceptable salts thereof. In certain embodiments, the disclosure relates to conjugate compounds or pharmaceutically acceptable salts thereof comprising an amino acid ester or a sphingolipid or derivative linked by a phosphorus oxide to a nucleotide or nucleoside. In certain embodiments, the disclosure contemplates pharmaceutical compositions comprising these compounds for uses in treating infectious diseases, viral infections, and cancer.

Phosphonate analogues of arabinose 5-phosphate: Putative ligands for arabinose 5-phosphate isomerases

Metabolically stable arabinose 5-phosphate analogues possessing phosphate mimetic groups at the 5-position were synthesized and evaluated by saturation-transfer-difference (STD) NMR studies for their ability to interact with arabinose 5-phosphate isomeras

Exploring the conformational and biological versatility of β-turn-modified gramicidin s by using sugar amino acid homologues that vary in ring size

Monobenzylated sugar amino acids (SAAs) that differ in ether ring size (containing an oxetane, furanoid, and pyranoid ring) were synthesized and incorporated in one of the β-turn regions of the cyclo-decapeptide gramicidin S (GS). CD, NMR spectroscopy, mo